{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:12:23Z","timestamp":1791821543599,"version":"4.3.4"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2010,2,24]]},"abstract":"Context<\/jats:title>High on-treatment platelet reactivity is associated with atherothrombotic events following coronary stent implantation.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the capability of multiple platelet function tests to predict clinical outcome.<\/jats:p><\/jats:sec>Design, Setting, and Patients<\/jats:title>Prospective, observational, single-center cohort study of 1069 consecutive patients taking clopidogrel undergoing elective coronary stent implantation between December 2005 and December 2007. On-treatment platelet reactivity was measured in parallel by light transmittance aggregometry, VerifyNow P2Y12 and Plateletworks assays, and the IMPACT-R and the platelet function analysis system (PFA-100) (with the Dade PFA collagen\/adenosine diphosphate (ADP) cartridge and Innovance PFA P2Y). Cutoff values for high on-treatment platelet reactivity were established by receiver operating characteristic curve (ROC) analysis.<\/jats:p><\/jats:sec>Main Outcome Measurement<\/jats:title>The primary end point was defined as a composite of all-cause death, nonfatal acute myocardial infarction, stent thrombosis, and ischemic stroke. The primary safety end point included TIMI (Thrombolysis In Myocardial Infarction) criteria major and minor bleeding.<\/jats:p><\/jats:sec>Results<\/jats:title>Kaplan-Meier analysis demonstrated that at 1-year follow-up, the primary end point occurred more frequently in patients with high on-treatment platelet reactivity when assessed by light transmittance aggregometry (52 [11.7%; 95% confidence interval {CI}, 8.9%-15.0%] vs 36 [6.0%; 95% CI, 4.2%-8.2%] P<\/jats:italic>\u00a0&amp;lt;\u00a0.001; n\u00a0=\u00a01049), VerifyNow (54 [13.3%; 95% CI, 10.2%-17.0%] vs 37 [5.7%; 95% CI, 4.1%-7.8%] P<\/jats:italic>\u00a0&amp;lt;\u00a0.001; n\u00a0=\u00a01052), Plateletworks (33 [12.6%; 95% CI, 8.8%-17.2%] vs 21 [6.1%; 95% CI, 3.8%-9.2%] P<\/jats:italic>\u00a0=\u00a0.005; n\u00a0=\u00a0606), and Innovance PFA P2Y (18 [12.2%; 95% CI; 7.4%-18.6%] vs 28 [6.3%; 95% CI, 4.3%-8.9%] P<\/jats:italic>\u00a0=\u00a0.02; n\u00a0=\u00a0588). ROC-curve analysis demonstrated that light transmittance aggregometry (area under the curve [AUC], 0.63; 95% CI, 0.58-0.68), VerifyNow (AUC, 0.62; 95% CI, 0.57-0.67), and Plateletworks (AUC, 0.61; 95% CI, 0.53-0.69) had modest ability to discriminate between patients with and without primary end point at 1-year follow-up. The IMPACT-R (n\u00a0=\u00a0905) and the Siemens PFA Collagen\/ADP (n\u00a0=\u00a0812) were unable to discriminate between patients with and without the primary end point at 1-year follow-up (all AUCs included 0.50 in the CI). None of the tests identified patients at risk for bleeding.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Of the platelet function tests assessed, light transmittance aggregometry, VerifyNow, Plateletworks, and Innovance PFA P2Y were significantly associated with the primary end point. However, the predictive accuracy of these 4 tests was only modest. None of the tests provided accurate prognostic information to identify patients at higher risk of bleeding following stent implantation.<\/jats:p><\/jats:sec>Trial Registration<\/jats:bold><\/jats:title>clinicaltrials.gov Identifier: NCT00352014<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2010.181","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T16:18:00Z","timestamp":1266941880000},"page":"754","source":"Crossref","is-referenced-by-count":704,"title":["Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation"],"prefix":"10.1001","volume":"303","author":[{"given":"Nicoline J.","family":"Breet","sequence":"first","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem W.","family":"van Werkum","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen J.","family":"Bouman","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes C.","family":"Kelder","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk J. T.","family":"Ruven","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert T.","family":"Bal","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H.","family":"Deneer","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankie M.","family":"Harmsze","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A. S.","family":"van der Heyden","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno J. W. M.","family":"Rensing","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Hackeng","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Author Affiliations: Departments of Cardiology (Drs Breet, van Werkum, Kelder, Bal, van der Heyden, Rensing, Suttorp, and ten Berg and Ms Bouman), Clinical Chemistry (Drs Ruven and Hackeng), and Clinical Pharmacy (Drs Deneer and Harmsze), St Antonius Hospital; and St Antonius Center for Platelet Function Research (Drs Breet, van Werkum, Kelder, Deneer, Harmsze, Hackeng, and ten Berg and Ms Bouman), Nieuwegein, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"ref-joc05010-1","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"9281","key":"ref-joc05010-2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"25","key":"ref-joc05010-3","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"ref-joc05010-4","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"ref-joc05010-5","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/eurheartj\/ehl275","article-title":"Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation","volume":"27","author":"Geisler","year":"2006","journal-title":"Eur Heart J"},{"issue":"9","key":"ref-joc05010-6","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ref-joc05010-7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"ref-joc05010-8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"issue":"10","key":"ref-joc05010-9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref-joc05010-10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"ref-joc05010-11","first-page":"e166","article-title":"ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"17","key":"ref-joc05010-12","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"ref-joc05010-14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/09537100802317918","article-title":"The use of the VerifyNow system to monitor antiplatelet therapy","volume":"19","author":"van Werkum","year":"2008","journal-title":"Platelets"},{"key":"ref-joc05010-15","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1111\/j.1538-7836.2006.02187.x","article-title":"A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention","volume":"4","author":"van Werkum","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref-joc05010-16","article-title":"A comparison between the Plateletworkstrade mark-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel [published online ahead of print December 15, 2008]","author":"van Werkum","journal-title":"Int J Cardiol"},{"issue":"1-2","key":"ref-joc05010-17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000093548","article-title":"Impact\u2013the cone and plate(let) analyzer","volume":"35","author":"Savion","year":"2006","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"11","key":"ref-joc05010-18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/j.1538-7836.2009.03585.x","article-title":"Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests","volume":"7","author":"Pittens","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"ref-joc05010-19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"ref-joc05010-20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","article-title":"Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study","volume":"52","author":"Patti","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"ref-joc05010-21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.carrev.2008.05.002","article-title":"Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents","volume":"9","author":"Shaw","year":"2008","journal-title":"Cardiovasc Revasc Med"},{"issue":"4","key":"ref-joc05010-22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/01.CIR.91.4.979","article-title":"Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty","volume":"91","author":"Stein","year":"1995","journal-title":"Circulation"},{"key":"ref-joc05010-23","first-page":"IV-457","article-title":"Clinical predictors of major atherothrombotic events 1 year following elective PCI","volume":"108","author":"Steinhubl","year":"2003","journal-title":"Circulation"},{"issue":"16","key":"ref-joc05010-24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref-joc05010-25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"ref-joc05010-26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH09-05-0285","article-title":"The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests","volume":"102","author":"Elsenberg","year":"2009","journal-title":"Thromb Haemost"},{"issue":"1","key":"ref-joc05010-27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"ref-joc05010-13","unstructured":"TIMI Study Group. Definitions used in TIMI-trials.. http:\/\/www.timi.org. Accessed August 1, 2009."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/185434\/joc05010_754_762_1756492673.48623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:00:18Z","timestamp":1756494018000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/185434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,2,24]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2010.181","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}